Top

Published in:

01-02-2013 | Research Article

Association of human herpes, papilloma and polyoma virus families with bladder cancer

Authors: Georgios I. Panagiotakis, Danae Papadogianni, Maria N. Chatziioannou, Ismini Lasithiotaki, Dimitrios Delakas, Demetrios A. Spandidos

Published in: Tumor Biology | Issue 1/2013

Abstract

The aim of the present study was to assess the possible etiologic role of human papillomavirus (HPV), human herpes virus (HHV) and the human polyoma virus families (BKV and JCV) in the tumourigenesis of bladder cancer. Thirty biopsy specimens from patients with different grades and stages of bladder cancer, who underwent transurethral bladder cancer resection, and 30 normal bladder mucosa specimens were analysed using polymerase chain reaction (PCR) for the detection of the above three virus family members. The presence of HPV was determined in all specimens with nested PCR and real-time quantitative PCR. All cancerous specimens, including the control group, were found to be negative both by PCR and real-time qPCR for the presence of HPV DNA, whilst all samples examined by PCR tested negative for the presence of HSV-1,2 Varicella zoster virus and HSV-7 DNA. Cytomegalovirus, HHV-6 and HHV-8 exhibited similar incidence in sample positivity in both cancerous and healthy tissues. EBV showed a higher prevalence in bladder cancer specimens compared to healthy tissue (p = 0.048), whilst BKV and JCV were detected only in tumour samples. The presence of EBV in a significant proportion of bladder tumours indicates the etiological role of this virus in cancer tumourigenesis.

Available only for authorised users

Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10:311–22.PubMedCrossRef

Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239–49.PubMedCrossRef

Mammas IN, Sourvinos G, Michael C, Spandidos DA. Human papilloma virus in hyperplastic tonsillar and adenoid tissues in children. Pediatr Infect Dis J. 2006;25:1158–62.PubMedCrossRef

Zderic SA, Carpiniello VL, Malloy TR, Rando RF. Urological applications of human papillomavirus typing using deoxyribonucleic acid probes for the diagnosis and treatment of genital condyloma. J Urol. 1989;141:63–5.PubMed

Libby JM, Frankel JM, Scardino PT. Condyloma acuminatum of the bladder and associated urothelial malignancy. J Urol. 1985;134:134–6.PubMed

Mevorach RA, Cos LR, di Sant’Agnese PA, Stoler M. Human papillomavirus type 6 in grade I transitional cell carcinoma of the urethra. J Urol. 1990;143:126–8.PubMed

Di Paolo JA, Woodworth CD, Popescu NC, Koval DL, Lopez JV, Doniger J. HSV-2-induced tumorigenicity in HPV-16 immortalized human genital keratinocytes. Virology. 1990;177:777–9.CrossRef

Hildesheim A, Mann V, Brinton LA, Szklo M, Reeves WC, Rawls WE. Herpes simplex virus type 2: a possible interaction with human papilloma virus types 16/18 in the development of invasive cervical cancer. Int J Cancer. 1991;49:335–40.PubMedCrossRef

Kjaer SK, De Villiers EM, Çaglayan H, Svare E, Haugaard BJ, Engholm G, et al. Human papillomavirus, herpes simplex virus and other potential risk factors for cervical cancer in a high-risk area (Greenland) and a low-risk area (Denmark)—a second look. Br J Cancer. 1993;67:830–7.PubMedCrossRef

10.

Schmauz R, Okong P, De Villiers E-M, Dennin R, Brade L, Lwanga SK, et al. Multiple infections in cases of cervical cancer from a high-incidence area in tropical Africa. Int J Cancer. 1989;43:805–9.PubMedCrossRef

11.

Landers RJ, O’Leary JJ, Crowley M, Annis P, Burke L, O’Brien D, et al. Epstein–Barr virus in normal, premalignant lesions of the uterine cervix. J Clin Pathol. 1993;46:931–5.PubMedCrossRef

12.

Wong KY, Colins RJ, Srivastava G, Pittaluga S, Cheung ANY, Wong LC. Epstein–Barr virus in carcinoma of the cervix. Intern J Gynec Pathol. 1993;12:224–7.CrossRef

13.

Israele V, Shirley P, Sixbey JW. Excretion of the Epstein–Barr virus from the genital tract of men. J Infect Dis. 1991;163:1341–3.PubMedCrossRef

14.

Hung SY, Tseng HH, Chung HM. Nephrogenic adenoma associated with cytomegalovirus infection of the ureter in a renal transplant patient: presentation as ureteral obstruction. Transpl Int. 2001;14:111–4.PubMedCrossRef

15.

Escudero AL, Luque RJ, Quintero A, Alvarez-Kindelan J, Requena M, Montironi R, et al. Association of human herpesvirus type 6 DNA with human bladder cancer. Cancer Lett. 2005;230:20–4.PubMedCrossRef

16.

Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci USA. 1996;93:14862–7.

17.

Major EO. Human polyomavirus. In: Knipe D, Howley PM, editors. Fields virology, 4th edition, vol. 2 (edited by Lipincott). Philadelphia: Williams & Wilkins; 2001. p. 2175–96.

18.

Weinreb DB, Desman GT, Amolat-Apiado MJM, Burstein DE, Jr Godbold JH, Johnson EM. Polyoma virus infection is a prominent risk factor for bladder carcinoma in immunocompetent individuals. Diagn Cytopathol. 2006;34:201–3.PubMedCrossRef

19.

De Roda Husman A-M, Walboomers JMM, van den Brule AJC, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol. 1995;76:1057–62.CrossRef

20.

Neofytou E, Sourvinos G, Asmarianaki M, Spandidos DA, Makrigiannakis A. Prevalence of human herpes virus types 1–7 in the semen of men attending an infertility clinic and correlation with semen parameters. Fertil Steril. 2009;91:2487–94.PubMedCrossRef

21.

Balis V, Sourvinos G, Soulitzis N, Giannikaki E, Sofras F, Spandidos DA. Prevalence of BK virus and human papillomavirus in human prostate cancer. Int J Biol Markers. 2007;22:245–51.PubMed

22.

Dokianakis DN, Sourvinos G, Sakkas S, Athanasiadou E, Spandidos DA. Detection of HPV and ras gene mutations in cervical smears from female genital lesions. Oncol Rep. 1998;5:1195–8.PubMed

23.

Panagiotakis SH, Soufla G, Baritaki S, Sourvinos G, Passam A, Zagoreos I, et al. Concurrent CMV and EBV DNAemia is significantly correlated with a delay in the response to HAART in treatment-naive HIV type 1-positive patients. AIDS Res Hum Retrovir. 2007;23:10–8.PubMedCrossRef

24.

Baltogiannis D, Tasos A, Voutsinas G, Dauaher H, Chambilomatis P, Giannakopoulos X. Bladder cancer mortality in the Epirus district population (Greece). Int Urol Nephrol. 2001;32:377–9.PubMedCrossRef

25.

Koffa M, Koumantakis E, Ergazaki M, Tsatsanis C, Spandidos DA. Association of herpesvirus infection with the development of genital cancer. Int J Cancer. 1995;63:58–62.PubMedCrossRef

26.

Chuang KL, Pang ST, Liao SK, Wu CT, Chang YH, Chuang HC, et al. Epstein–Barr virus DNA load in tumour tissues correlates with poor differentiation status in non-muscle invasive urothelial carcinomas. BJU Int. 2011;107:150–4.PubMedCrossRef

27.

Gazzaniga P, Vercillo R, Gradilone A, Silvestri I, Gandini O, Napolitano M, et al. Prevalence of papillomavirus, Epstein–Barr virus, cytomegalovirus, and herpes simplex virus type 2 in urinary bladder cancer. J Med Virol. 1998;55:262–7.PubMedCrossRef

28.

Polesel J, Gheit T, Talamini R, Shahzad N, Lenardon O, Sylla B, et al. Urinary human polyomavirus and papillomavirus infection and bladder cancer risk. Br J Cancer. 2012;106:222–6.PubMedCrossRef

29.

Rollison DE, Sexton WJ, Rodriguez AR, Kang LC, Daniel R, Shah KV. Lack of BK virus DNA sequences in most transitional-cell carcinomas of the bladder. Int J Cancer. 2007;120:1248–51.PubMedCrossRef

30.

Loghavi S, Bose S. Polyomavirus infection and urothelial carcinoma. Diagn Cytopathol. 2011;39:531–5.PubMedCrossRef

31.

Anwar K, Naiki H, Nakakuki K, Inuzuka M. High frequency of human papillomavirus infection in carcinoma of the urinary bladder. Cancer. 1992;70:1967–73.PubMedCrossRef

32.

Boucher NR, Scholefield JH, Anderson JB. The aetiological significance of human papillomavirus in bladder cancer. Br J Urol. 1996;78:866–9.PubMedCrossRef

33.

Chang F, Lipponen P, Tervahauta A, Syrjänen S, Syrjänen K. Transitional cell carcinoma of the bladder: failure to demonstrate human papillomavirus deoxyribonucleic acid by in situ hybridization and polymerase chain reaction. J Urol. 1994;152:1429–33.PubMed

34.

Shigehara K, Sasagawa T, Kawaguchi S, Nakashima T, Shimamura M, Maeda Y, et al. Etiologic role of human papillomavirus infection in bladder carcinoma. Cancer. 2011;117:2067–76.PubMedCrossRef

35.

Li N, Yang L, Zhang Y, Zhao P, Zheng T, Dai M. Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis. 2011;204:217–23.PubMedCrossRef

36.

Alexander RE, Hu Y, Kum JB, Montironi R, Lopez-Beltran A, Maclennan GT, Idrees MT, Emerson RE, Ulbright TM, Grignon DG, Eble JN, Cheng L. p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. Mod Pathol. 2012 Jun 8. doi:10.1038/modpathol.2012.103.

37.

Ben Selma W, Ziadi S, Ben Gacem R, Amara K, Ksiaa F, Hachana M, et al. Investigation of human papillomavirus in bladder cancer in a series of Tunisian patients. Pathol Res Pract. 2010;15:740–3.CrossRef

38.

Badawi H, Ahmed H, Ismail A, Diab M, Moubarak M, Badawy A, et al. Role of human papillomavirus types 16, 18, and 52 in recurrent cystitis and urinary bladder cancer among Egyptian patients. Medsc J Med. 2008;10:232.

39.

Moonen PM, Bakkers JM, Kiemeney LA, Schalken JA, Melchers WJ, Witjes JA. Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol. 2007;52:464–8.PubMedCrossRef

Title: Association of human herpes, papilloma and polyoma virus families with bladder cancer
Authors: Georgios I. Panagiotakis
Danae Papadogianni
Maria N. Chatziioannou
Ismini Lasithiotaki
Dimitrios Delakas
Demetrios A. Spandidos
Publication date: 01-02-2013
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 1/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-012-0512-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

CLEIA CA125 evidences: good analytical performance avoiding “Hook effect”

High expression of AP-4 predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy

Bone marrow-derived cells contribute to NDEA-induced lung squamous cell carcinoma

The role of novel biomarker HE4 in endometrial cancer: a case control prospective study

Downregulation of Skp2 inhibits the growth and metastasis of gastric cancer cells in vitro and in vivo

Expression of the coxsackie and adenovirus receptor in human lung cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer